Batch Reactor Production Routes for Pharmaceutical Intermediate Synthesis are central to the development and manufacturing of high-purity pharmaceutical ingredients. Identified under its specified CAS number, this intermediate is defined by its unique molecular formula and precise molecular weight, crucial attributes for maintaining consistency in pharmaceutical synthesis. The compound's structure is further characterized by its IUPAC designation and InChIKey, which serve as essential tools for clear and unmistakable identification throughout the chemical supply chain. This substance is primarily classified as a pharmaceutical intermediate—a key building block that enables the creation of active pharmaceutical ingredients by providing critical precursor structures during synthetic routes.
When considering the physical and chemical specifications of this intermediate, only verified attributes are included. The data comprise measurable parameters such as boiling point, melting point, density, flash point, and vapor pressure, depending on the available information. These characteristics are vital for determining handling procedures, equipment choices, and safety protocols within batch reactor operations.
Compliance with global regulatory standards remains a cornerstone of pharmaceutical manufacturing. The registration status under the EU REACH framework is stated by its specific article and relevant tonnage band, offering transparency regarding import and production volumes. U.S. regulatory alignment is ensured by confirmation of listing on the TSCA inventory, citing the pertinent section reference. Industry-wide guidelines, such as those outlined in ICH quality standards—always denoted with the full code, including revision and specific limit—set strict benchmarks for impurity profiles and allowable contaminants. Classification under the Globally Harmonized System (GHS) provides clear identification of any hazard classes assigned to this intermediate, with full disclosure of signal words and H-phrases as needed. If the compound is referenced in official pharmacopeia monographs, these chapter numbers are cited to guide analytical and quality practices. Occupational exposure limits, such as OSHA's Permissible Exposure Limits (PEL) and NIOSH's Recommended Exposure Limits (REL), are included whenever established.
In the realm of pharmaceutical development, this intermediate is utilized as a pivotal component in synthetic routes to high-value drugs and advanced intermediates. Its role may extend to the formation of targeted functional groups or scaffold elements that facilitate downstream modifications. While its presence is essential to the assembly of final active pharmaceutical ingredients, its function is confined to molecular construction rather than providing direct therapeutic action.
Standard handling practices for batch reactor intermediates include packaging in 25-kilogram drums, 200-kilogram drums, and intermediate bulk containers (IBCs) to support both pilot and commercial scale operations. Optimal storage conditions are determined based on available GHS data on chemical stability, with recommendations favoring cool, dry, and well-ventilated environments away from incompatible substances. Shelf life, consistent with industry standards for this class of pharmaceuticals, is typically defined to maintain product quality and efficacy over extended periods.
The information provided is supported by recognized sources, including PubChem, the NIST Chemistry WebBook, the European Chemicals Agency (ECHA), and the EPA TSCA Inventory. These resources ensure that manufacturers and stakeholders have access to reliable, regulatory-compliant guidance for the safe and effective use of Batch Reactor Production Routes for Pharmaceutical Intermediate Synthesis in drug development.
Sources
PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/{cid}
NIST: https://webbook.nist.gov/cgi/cbook.cgi?Name={cas_number}
ECHA: {echa_url}
EPA TSCA: https://www.epa.gov/tsca-inventory
Related Articles
